https://www.selleckchem.com/pr....oducts/protosappanin
Adoptive cell therapy (ACT), such as chimeric antigen receptor (CAR) T-cell therapy, has demonstrated promising therapeutic effects with potentially non-monotonic dose-response curves. Building upon the i3 + 3 design for cytotoxic agents [1], we propose a new method - joint i3 + 3 (Ji3 + 3) that takes into account of both safety and efficacy outcomes in making dosing recommendations. This allows for efficient dose escalation and identification of biological optimal dose of ACTs which may not be cytotoxic. The Ji3 + 3 design is r
Like
Comment
Share
